Advertisement

Pharmaka mit Wirkung auf die Blutgerinnung

  • C. Taube
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Die Fähigkeit des Organismus zum — mitunter lebensrettenden — Verschluß verletzter Blutgefäße, Hämostase genannt, beruht auf einem Zusammenspiel von Gefäßwand, Thrombozyten und plasma-tischem Gerinnungs- und Fibrinolysesystem, als dessen Folge ein sich bildender Fibrinpfropf das kontrahierte Gefäß vorläufig verschließt. Wir wissen heute, daß intravasal ständig Gerinnungs- und Fibrinolysevorgänge ablaufen, die die Bildung und den Abbau von Fibrin in einem physiologischen Gleichgewicht halten. Bei pathologischen Veränderungen kann jedoch verstärkt eine intravasale Gerinnung mit Thrombenbildung oder eine gesteigerte Fibrinolyse mit Blutungsneigung auftreten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anderson HV, Willerson JT (1993) Thrombolysis in acute myocardial infarction. N Engl J Med 329:703–709PubMedCrossRefGoogle Scholar
  2. Ansell JE (1993) Oral anticoagulant therapy: 50 years later. Arch Intern Med 153:586–596PubMedCrossRefGoogle Scholar
  3. Becker RC (1993) Thrombolytic agents and anticoagulants. Cardiovasc Drugs Ther 7:825–828PubMedCrossRefGoogle Scholar
  4. Bichler J, Fritz H (1991) Hirudin, a new therapeutic tool? Ann Hematol 63:67–76PubMedCrossRefGoogle Scholar
  5. Bode C, Baumann H, Hodenberg E von, Kübier W (1992) Thrombolytische Therapie des akuten Myocardinfarktes. Med Klin 87:64–69Google Scholar
  6. Bower S, Sandercock P (1993) Antiplatelet and anticoagulant therapy. Curr Opin Neurol Neurosurg 6:55–59PubMedGoogle Scholar
  7. Chesebro JH, Opie LH, Fuster V (1989) The recent trials for aspirin in the prevention of cardiovascular mortality. Cardiovasc Drug Ther 3:353–354CrossRefGoogle Scholar
  8. Cielinski G, Klepzig H (1993) Therapie des frischen Myokardinfarkts mit Thrombolytika. Fortschr Med 111:209–213Google Scholar
  9. Clarke RJ, Mayo G, Price P, FitzGerald GA (1992) Suppression of thromboxane A2 but not of systemic prostacyclin by con-trolled-release aspirin. N Engl J Med 325:1137–1141CrossRefGoogle Scholar
  10. Collen D, Lijnen HR (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114–3124PubMedGoogle Scholar
  11. Coller BS (1992) Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med 43:171–180PubMedCrossRefGoogle Scholar
  12. Davie EW, Ichinose A, Leytus SP (1986) Structural features of the proteins participating in blood coagulation and fibrinolysis. Cold Spring Symp Quant Biol 51:509–514CrossRefGoogle Scholar
  13. Dettori AG, Babbini M (1992) Human pharmacology of a low-molecular-weight heparin (alpha-LMWH): An update. Med Res Rev 12:373–389PubMedCrossRefGoogle Scholar
  14. DiMinno G, Cerbone AM, Mattiolo PL, Turco S, Iovine C, Mancini M (1985) Functionally thrombasthenic state in normal platelets following administration of ticlopidine. J. Clin Invest 75:328–338CrossRefGoogle Scholar
  15. Doutremepuich C, Seze O de, LeRoy D, Lalanne MC, Anne MC (1990) Aspirin at very ultra low dosage in healthy volunteers: Effects on bleeding time, platelet aggregation and coagulation. Haemostasis 20:99–105PubMedGoogle Scholar
  16. Esmon CT (1987) The regulation of natural anticoagulant pathways. Science 235–1348–1352PubMedCrossRefGoogle Scholar
  17. Fareed J, Bacher P, Messmore HL (1992) Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Prog Cardiovasc Dis 34:379–398PubMedCrossRefGoogle Scholar
  18. Furie B, Furie CB (1992) Molecular and cellular biology of blood coagulation. N Engl J Med 326:800–806PubMedCrossRefGoogle Scholar
  19. Fuster V, Dyken ML, Vokonas PS, Hennekens C (1993) Aspirin as a therapeutic agent in cardiovascular disease. Circulation 87:659–675PubMedGoogle Scholar
  20. Gallus AS (1994) Anticoagulants and antiplatelets drugs. Med J Aust 160:78–82PubMedGoogle Scholar
  21. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensin AW (1994) Low molecular weight Heparin: A critical analysis of clinical trials. Pharmacol Rev 46:89–109PubMedGoogle Scholar
  22. Grotta J, Norris JW, Kamm B (1992) Prevention of stroke with ticlopidine: Who benefits most? Neurology 42:111–115PubMedGoogle Scholar
  23. Görge G, Meyer J (1992) Die Wahl geeigneter Thrombolytika zur Therapie des akuten Herzinfarktes. Med Klin 87:70–80Google Scholar
  24. Groos M (1994) Lokal applizierte Acetylsalicylsäure hemmt Thromboxan A2-Bildung. Arzneimitteltherapie 12:121–122Google Scholar
  25. GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682CrossRefGoogle Scholar
  26. Haberl RK, Tiecks FP (1993) Azetylsalizylsäure und Ticlopidin in der Schlaganfallprophylaxe. Psycho 19:763–768Google Scholar
  27. Hampton JR, Schroder R, Wilcox RG et al. (1995) Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 346:329–336CrossRefGoogle Scholar
  28. Hauptmann J, Markwardt F (1992) Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Semin Thromb Hemostasis 18:200–217CrossRefGoogle Scholar
  29. Hirsh J (1991) Heparin. N Engl J Med 324:1565–1574CrossRefGoogle Scholar
  30. Hirsh J (1991) Oral anticoagulant drugs. N Engl J Med 324:1865–1875PubMedCrossRefGoogle Scholar
  31. Hirsh J, Fuster V (1994) Guide to anticoagulant therapy, 1. Heparin, Circulation 89:1449–1468PubMedGoogle Scholar
  32. Hirsh J, Fuster V (1994) Guide to anticoagulant therapy, 2. Oral anticoagulants, Circulation 89:1469–1480PubMedGoogle Scholar
  33. Hourani SMO, Cusack NJ (1991) Pharmacological receptors on blood platelets. Pharmacol Rev 43:243–298PubMedGoogle Scholar
  34. Hoyer LW (1994) Hemophilia A. N Engl J Med 330:38–47PubMedCrossRefGoogle Scholar
  35. Johnson PH (1994) Hirudin: Clinical potential of a thrombin inhibitor. Annu Rev Med 45:165–177PubMedCrossRefGoogle Scholar
  36. Kakkar VV, Cohen AT, Edmonson RA (1993) Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 341:259–265PubMedCrossRefGoogle Scholar
  37. Kandrotas RJ (1992) Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 22:359–374PubMedCrossRefGoogle Scholar
  38. Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ (1993) Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelets cycloxoygenase and preserves prostacyclin biosynthesis. Circulation 88:556–561PubMedGoogle Scholar
  39. Link KP (1959) The discovery of dicumarol and its sequels. Circulation 19:97–107PubMedGoogle Scholar
  40. Marktreiter M, Essen R v, (1994) Heutiger Stand der präklinischen Infarkttherapie. Fortschr Med 112:113–116Google Scholar
  41. Marder VJ, Butler FA, Barlow GH (1987) Antifibrinolytic therapy. In: Hemostasis and thrombosis: Basic principles and clinical practice, ed. by Colman RW, Hirsh, J. Marder VJ, Salsman EW. Lippincott Co Philadelphia, 380–394Google Scholar
  42. Markwardt F (ed) (1971) Antikoagulanzien, In: Handbook of experimental pharmacology, vol 27. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  43. Markwardt F (ed) (1978) Fibrinolytics and antifibrinolytics, In: Handbook of experimental Pharmacology, vol 46, Springer, Berlin Heidelberg New York, TokyoGoogle Scholar
  44. Markwardt F (1993) Hirudin: The famous anticoagulant agent. Adv Exp Med Biol 340:191–211PubMedGoogle Scholar
  45. McTavish D, Faulds D, Goa KL (1990) Ticlopidine: An update review of its pharmacology and therapeutic use in platelets dependent disorders, Drugs 40:238–259PubMedCrossRefGoogle Scholar
  46. Menache D, Grossman BJ, Jackson CM (1992) Antithrombin III: Physiology, deficiency, and replacement therapy. Transfusion 32:580–588PubMedCrossRefGoogle Scholar
  47. O’Reilly RA (1987) Warfarin metabolism and drug-drug interactions. Adv Exp Med Biol 214:205–212PubMedGoogle Scholar
  48. Ouyang C, Teng C-M, Huang T-F (1992) Characterization of snake venom components acting on blood coagulation and platelet function. Toxicon 30:945–966PubMedCrossRefGoogle Scholar
  49. Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330:1287–1294PubMedCrossRefGoogle Scholar
  50. Schrör K (ed) (1984) Prostaglandine und verwandte Verbindungen: Bildung, Funktion und pharmakologische Beeinflussung. Thieme Stuttgart New YorkGoogle Scholar
  51. Sinzinger H, Rogatti W (1991) PGE1 in der Therapie der peripheren arteriellen Durchblutungsstörung. Wien Klin Wo-chenschr 103:558–565Google Scholar
  52. Suttie JW (1987) The biochemical basis of warfarin therapy. Adv Exp Med Biol 214:3–16PubMedGoogle Scholar
  53. Suttie JW (1993) Synthesis of vitamin K-dependent proteins. FASEB J 7:445–452PubMedGoogle Scholar
  54. Topol EJ, Agnelli G (1991) Strategies for administration of tissue plasminogen activator. Mol Biol Med 8:219–234PubMedGoogle Scholar
  55. Turpie AGG, Gent CBM, Laupacis A (1993) A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 329:524–529PubMedCrossRefGoogle Scholar
  56. Warkentin TE, Kelton JG (1989) Heparin-induced thrombocytopenia. Annu Rev Med 40:31–44PubMedCrossRefGoogle Scholar
  57. Weiller C, Diener HC (1993) Ticlopidin — Sekundärprävention des ischämischen Schlaganfalls, Arzneimitteltherapie 11: 182–189Google Scholar
  58. Wilcox RG (1995) Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 346:329–336CrossRefGoogle Scholar
  59. Wilcox RG, Olsson CG, Skene AM, Lippe G,m Jensen G, Hampton JR (1988) Trial of t-PA for mortality reduction in acute myocardial infarction. Lancet 2:525–530PubMedCrossRefGoogle Scholar
  60. Weitz JI, Hirsh J (1992) Antithrombins: Their potential as antithrombotic agents. Annu Rev Med 43:9–16PubMedCrossRefGoogle Scholar
  61. Weitz JI, Hirsh J (1993) New anticoagulant strategies. J Lab Clin Med 122:364–373PubMedGoogle Scholar
  62. Willard JE, Lange RA, Hillis LD (1992) The use of aspirin in ischemic heart disease. N Engl J Med 327, 175–181PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • C. Taube

There are no affiliations available

Personalised recommendations